



SpinalCyte Announces New Japanese Patent

October 15, 2019 HOUSTON, TX--SpinalCyte, LLC, a Texas-based regenerative medicine company focused on regrowth of the spinal disc using Human Dermal Fibroblasts (HDFs), today announced the issuance of a new Japanese Patent. The company's patent portfolio now includes 58 U.S. and International patents issued with 100+ patents pending focused on the clinical use of fibroblasts.

"This Japanese Patent provides broad protection in the Japanese market and advances our worldwide leading position in fibroblast cell therapy," said Pete O'Heeron, Chief Executive Officer of SpinalCyte. "As we continue to expand our therapeutic capabilities of fibroblasts, we will add to our existing portfolio of intellectual property."

The Japanese Patent No. 6574502 titled "Generation of Cartilage Ex Vivo From Fibroblasts," describes methods to differentiate fibroblast cells into cartilage in a controlled environment, which will lead to implantation of the new cartilage.

About Degenerative Disc Disease

Degenerative disc disease (DDD) is a condition in which a patient's spinal disc breaks down and can begin to collapse. It is estimated that 85% of people over the age of 50 have evidence of disc degeneration and over 1.3 million procedures a year are performed to treat the disease. The most common treatments for patients with DDD are either discectomy or spinal fusion. Discectomy is the partial or full removal of the degenerated disc to decompress and relieve the nervous system but can cause long term spinal pain. In a spinal fusion procedure, the entire disc is removed and the two adjacent vertebrae are fused together. It often increases strain on the adjacent discs and surrounding tissues leading to further degeneration.

About CybroCell

CybroCell is the first off-the-shelf allogenic human dermal fibroblast (HDF) product for the treatment of degenerative disc disease. SpinalCyte's Phase 1/Phase 2 clinical trial for injected human dermal fibroblasts in the treatment of DDD demonstrated after 12 months, patients injected with CybroCell had sustained improvement in pain relief and increased back mobility.

About SpinalCyte

Based in Houston, Texas, SpinalCyte, LLC, is a regenerative medicine company developing an innovative solution for spinal replacement using human dermal fibroblasts. Currently, SpinalCyte holds 58 U.S. and international issued patents and has filed for an additional 100+ patents pending and issued across a variety of clinical pathways, including Disc Degeneration, Multiple Sclerosis, Parkinson's, Chronic Traumatic Encephalopathy, Cancer, Diabetes, Liver Failure and Heart Failure. Funded entirely by angel investors, SpinalCyte represents the next generation of medical advancement in cell therapy. Visit www.spinalcyte.com.

Contact:

Clinical Contact:

info@spinalcyte.com